Literature DB >> 19417024

Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer.

Shinae Kizaka-Kondoh1, Satoshi Itasaka, Lihua Zeng, Shotaro Tanaka, Tao Zhao, Yumi Takahashi, Keiko Shibuya, Kiichi Hirota, Gregg L Semenza, Masahiro Hiraoka.   

Abstract

PURPOSE: Pancreatic cancer is characterized by intratumoral hypoxia, early and aggressive local invasion, and metastatic potential. Hypoxia-inducible factor-1 (HIF-1) is the major transcriptional activator of hypoxia-responsive genes and intratumoral hypoxia is associated with increased risk of metastasis. However, the behavior of the cells having HIF-1 activity during the malignant progression in pancreatic cancer has not been tested. EXPERIMENTAL
DESIGN: We orthotopically transplanted pancreatic cancer cells stably transfected with a HIF-1-dependent luciferase reporter gene and monitored HIF-1 activity in vivo in control and POP33-treated mice. POP33 is a novel prodrug, which has potential to increase caspase-3 activity and induce apoptosis in HIF-1-active/hypoxic cells.
RESULTS: In vivo optical imaging showed that HIF-1 activity proceeded along with local invasion, the peritoneal dissemination, and the liver metastasis. HIF-1-active hypoxic cells were selectively eradicated by POP33. Moreover, selective killing of HIF-1-active hypoxic cells significantly suppressed malignant progression, resulting in a significant improvement in survival rate.
CONCLUSIONS: These results show that HIF-1-active cells constitute a large proportion of invading and metastatic cells and suggest that eradication of these cells may improve the outcome in advanced pancreatic cancer, a condition for which no effective therapy currently exists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417024     DOI: 10.1158/1078-0432.CCR-08-2267

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination.

Authors:  Fumiko Taguchi; Yasuo Kodera; Yasufumi Katanasaka; Kazuyoshi Yanagihara; Tomohide Tamura; Fumiaki Koizumi
Journal:  Invest New Drugs       Date:  2010-06-08       Impact factor: 3.850

2.  Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells.

Authors:  Jun Zhao; Chunhui Wu; James Abbruzzese; Rosa F Hwang; Chun Li
Journal:  Mol Pharm       Date:  2015-05-12       Impact factor: 4.939

3.  Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model.

Authors:  Tamami Higuchi; Takehiko Yokobori; Tomoharu Naito; Chihaya Kakinuma; Shinji Hagiwara; Masahiko Nishiyama; Takayuki Asao
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

Review 4.  Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer.

Authors:  Han Liu; Qingyong Ma; Qinhong Xu; Jianjun Lei; Xuqi Li; Zheng Wang; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Cancer-stromal interactions in scirrhous gastric carcinoma.

Authors:  Masakazu Yashiro; Kosei Hirakawa
Journal:  Cancer Microenviron       Date:  2010-01-26

Review 6.  Small Molecule Active Site Directed Tools for Studying Human Caspases.

Authors:  Marcin Poreba; Aleksandra Szalek; Paulina Kasperkiewicz; Wioletta Rut; Guy S Salvesen; Marcin Drag
Journal:  Chem Rev       Date:  2015-11-09       Impact factor: 60.622

7.  Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha.

Authors:  Masashi Ueda; Takashi Kudo; Yuji Kuge; Takahiro Mukai; Shotaro Tanaka; Hiroaki Konishi; Azusa Miyano; Masahiro Ono; Shinae Kizaka-Kondoh; Masahiro Hiraoka; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-29       Impact factor: 9.236

8.  PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative.

Authors:  Takashi Kudo; Masashi Ueda; Hiroaki Konishi; Hidekazu Kawashima; Yuji Kuge; Takahiro Mukai; Azusa Miyano; Shotaro Tanaka; Shinae Kizaka-Kondoh; Masahiro Hiraoka; Hideo Saji
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

9.  PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis.

Authors:  Angela Criscimanna; Li-Juan Duan; Julie A Rhodes; Volker Fendrich; Emily Wickline; Douglas J Hartman; Satdarshan P S Monga; Michael T Lotze; George K Gittes; Guo-Hua Fong; Farzad Esni
Journal:  Cancer Res       Date:  2013-06-07       Impact factor: 12.701

10.  Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation.

Authors:  Takashi Ushiki; Shinae Kizaka-Kondoh; Eishi Ashihara; Shotaro Tanaka; Masayoshi Masuko; Hideyo Hirai; Shinya Kimura; Yoshifusa Aizawa; Taira Maekawa; Masahiro Hiraoka
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.